Abstract: Described herein are transdermal parasiticidal formulations and methods of treatment and use, wherein the formulation is not only able to deliver an agent or agents through the skin layer, but is able to do so through wool, dirt and/or a sebum layer on the skin if such layers are present. The transdermal parasiticidal formulation may be a solution including a therapeutically effective amount of levamisole anthelmintic agent dissolved in a solution including isopropyl myristate and D-limonene. This base formulation is highly compatible with other compounds and various other actives may be added to this formulation.
Abstract: Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
Abstract: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Type:
Application
Filed:
November 13, 2014
Publication date:
October 8, 2015
Inventors:
Zhihui Qiu, Wing-Kee Philip Cho, Na Zhao, Victor Ming-She Wong
Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
Type:
Application
Filed:
June 23, 2015
Publication date:
October 8, 2015
Inventors:
Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
Abstract: Provided herein are methods of restoring vitamin D sensitivity in tumor cells that are vitamin D resistant. Also provided are methods of treating, preventing or managing cancer using an immunomodulatory compound in combination with a vitamin D agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
Type:
Application
Filed:
August 12, 2014
Publication date:
October 8, 2015
Inventors:
Carole Brosseau, Justin Blake Bartlett, Angus George Dalgleish, Kay Winifred Colston, Christine Galustian
Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.
Abstract: The present disclosure relates to a method of managing urolithiasis or related urological disorders in a subject in need thereof, using pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipient(s).
Abstract: The nitric ester of Saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, I useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic Addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, Guillain Barré syndrome, Hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematous, Type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis.
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Application
Filed:
June 3, 2015
Publication date:
October 8, 2015
Applicants:
The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Application
Filed:
June 3, 2015
Publication date:
October 8, 2015
Applicants:
The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Application
Filed:
June 3, 2015
Publication date:
October 8, 2015
Applicants:
PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed embodiments are related to compositions of a piperazine compound and a P450 inhibitor, including compositions of a piperazine compound and one or more P450 inhibitors, and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Type:
Application
Filed:
February 17, 2015
Publication date:
October 8, 2015
Inventors:
Jonathan Lim, Elena Ardini, Maria Menichincheri
Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Type:
Application
Filed:
March 31, 2015
Publication date:
October 8, 2015
Applicants:
ARADIGM CORPORATION, OREGON STATE UNIVERSITY
Inventors:
Igor GONDA, James BLANCHARD, David C. CIPOLLA, LUIZ EDUARDO MOREIRA BERMUDEZ
Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Abstract: A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a histone deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Abstract: 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC).
Abstract: The present invention provides a method for treating a cancer, comprising (a) identifying a patient with acquired resistance to an EGFR kinase inhibitor; and (b) administering to the patient an anti-cancer agent, and treating the patient with radiation therapy.
Abstract: Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.
Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
Type:
Application
Filed:
April 16, 2015
Publication date:
October 8, 2015
Inventors:
Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.
Type:
Application
Filed:
June 19, 2015
Publication date:
October 8, 2015
Inventors:
Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
Abstract: The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent. The invention further encompasses pharmaceutical compositions comprising an A1 adenosine receptor antagonist alone or with, at least, one additional therapeutic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing renal impairment.
Abstract: The invention relates to supporting the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract of an animal. Provided is the use of riboflavin, riboflavin phosphate or a salt thereof, for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of Faecalibacterium prausnitzii in the gastrointestinal tract. Also provided is a synbiotic composition comprising living beneficial butyrate-producing anaerobic bacteria formulated with riboflavin, riboflavin phosphate or a salt thereof, and cysteine.
Type:
Application
Filed:
November 1, 2013
Publication date:
October 8, 2015
Inventors:
Hermanus Josef Martinus Harmsen, Muhammad Tanweer Khan, Mehdi Sadaghian Sadabad, Jan Maarten Van Dijl
Abstract: The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of ?-catenin. The disclosure also relates to applications in the treatment of hyperproliferative and pre-cancerous skin conditions including actinic keratosis and psoriasis, and pharmaceutical compositions comprising such alpha helix mimetic ?-catenin inhibitors.
Abstract: A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
Abstract: Provided are methods of treating polycystic kidney disease in a subject in need thereof, by administering to the subject in need thereof, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods of treating polycystic kidney disease by a compound of formula (I) in combination with additional therapeutic agents.
Type:
Application
Filed:
October 18, 2013
Publication date:
October 8, 2015
Inventors:
David Proia, Erica Golemis, Tamina Seeger-Nukpezah
Abstract: The invention relates to the area of medicine, namely to the medicinal preparations, applied in clinical practice. The proposed medicinal preparation contains two non-miscible components, one allopathic medicinal preparation, and the second one is a homeopathic medicinal preparation. It features the second component obtained by potentiating of the first component diluted within the range from 6C to 30C and placed into blisters, con bottles, ampoules in the general secondary package with an allopathic component. Upon the termination or cancellation of an allopathic treatment course, the use of specific antidote—homeopathic component corrects the side effects, reduces the allergic reactions, accelerates the restorative processes in organism.
Abstract: Described herein are methods for reducing ventricular tachycardia/ventricular fibrillation (VT/VF), methods for reducing implantable cardioverter-defibrillator device (ICD) shocks, methods for reducing CV hospitalization, ER visits, CV death or SCD in patients having implantable cardiac devices or CRT, and methods for reducing the use of ICD in a human patient without prior VT/VF, by administering an effective amount of the potent and selective late sodium ion channel blocker Compound 1.
Type:
Application
Filed:
March 20, 2015
Publication date:
October 8, 2015
Inventors:
Luiz Belardinelli, Ewa Prokopczuk, Dewan Zeng
Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
Type:
Application
Filed:
June 22, 2015
Publication date:
October 8, 2015
Inventors:
Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
Abstract: Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
Type:
Application
Filed:
June 22, 2015
Publication date:
October 8, 2015
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Kyeong Soo KIM, Deokkyu LEE, Dong Ho KIM, Yong II KIM, Jae Hyun PARK, Jong Soo WOO
Abstract: Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and with defined levonorgestrel content. The invention relates to a pharmaceutical composition for oral contraception for a woman of fertile age consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Furthermore, the invention relates to a pharmaceutical preparation for oral contraception consisting of a number of separately packed and individually removable daily dosage units intended for consecutive daily oral administration, each dosage unit consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Additionally, the invention relates to a dosage regimen, i.e.
Type:
Application
Filed:
November 4, 2013
Publication date:
October 8, 2015
Applicant:
NAARI AG
Inventors:
Michael Oettel, Prithi S. Kochhar, Hermann Osterwald
Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
Abstract: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.
Type:
Application
Filed:
June 18, 2015
Publication date:
October 8, 2015
Inventors:
Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
Abstract: The present invention relates to the use of Fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that Fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality. The invention further provides an oral dosage unit comprising at least 500 mg, of Fosfestrol.
Type:
Application
Filed:
October 14, 2013
Publication date:
October 8, 2015
Applicant:
CHAMAELEO PHARMA BVBA
Inventors:
Johannes Jan Platteeuw, Martijn De Bree
Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
Type:
Application
Filed:
March 18, 2015
Publication date:
October 8, 2015
Inventors:
Anjan CHATTERJI, Grant COOPER, David SCHWARTZ
Abstract: Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulations or dry powder means or via nebulization. Oral forms are also suitable.
Abstract: A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.
Type:
Application
Filed:
October 21, 2014
Publication date:
October 8, 2015
Inventors:
John J. Koleng, Robert Florentine, David W. Anderson, David W. Anderson
Abstract: An anticancer agent containing ellagitannin, a combination use anticancer agent wherein the anticancer agent and an anticancer agent containing anthracyclines are used in combination.
Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.
Type:
Application
Filed:
April 13, 2015
Publication date:
October 8, 2015
Applicant:
POLY-MED, INC.
Inventors:
Shalaby W. Shalaby, Georgios T. Hilas, Shelia Nagatomi
Abstract: Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.
Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
Abstract: A topical treatment composition for treating muscle cramps, muscle stiffness, muscle pain or muscle spasms. The treatment composition includes a middle (mid) chain fatty acid (MCFA). A method of making the topical treatment composition is also disclosed herein.
Type:
Application
Filed:
April 2, 2015
Publication date:
October 8, 2015
Inventors:
Gary L. Rayburn, Robert D. Maurer, Marvin A. Cuchens
Abstract: Methods, compositions, and treatment protocols are provided in the current invention for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F2 gene expression or activity of protein. In one embodiment silencing, or substantial inhibition of NR2F2 expression is achieved through induction of RNA interference in cells associated with development of MDS. Induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition may be used to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states.
Abstract: The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease.
Abstract: The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing.
Abstract: This invention provides therapeutic treatments that prevent or ameliorate thrombocytopenia based on administration of small RNA fragments. More specifically, this invention provides an improved chemotherapeutic regimen that prevents or ameliorates bone marrow suppression and thrombocytopenia induced by anti-cancer drugs, wherein the chemotherapeutic regimen incorporates administration of small RNA fragments. Further, the present invention provides a therapeutic treatment for thrombocytopenia associated with immune disorders known as Immune Thrombocytopenic Purpura based on administration of small RNA fragments.
Abstract: A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.
Type:
Application
Filed:
April 30, 2015
Publication date:
October 8, 2015
Inventors:
Noah BEN-SHALOM, Zvi NEVO, Abraham PATCHORNIK, Dror ROBINSON